Hypofractionated RT, Conventional RT Comparable in Intermediate-Risk Prostate Cancer

Hypofractionated RT, Conventional RT Comparable in Intermediate-Risk Prostate Cancer

Hypofractionated regimen of precision radiotherapy was not inferior to conventional RT in patients with intermediate-risk prostate cancer.

Fluciclovine PET/CT Improves Targeted Radiation Treatment of Recurrent Prostate Cancer

Fluciclovine PET/CT Improves Targeted Radiation Treatment of Recurrent Prostate Cancer

F-18-fluciclovine PET helps detect and localize recurrent prostate cancer allowing for individualized, targeted therapy.

Single Fraction of HDR Brachytherapy Found Effective in Localized Prostate Cancer

Single Fraction of HDR Brachytherapy Found Effective in Localized Prostate Cancer

A single 19-Gy fraction of brachytherapy was found as effective as a longer regimen of low-dose-rate brachytherapy in localized prostate cancer.

Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer

Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer

Cabozantinib activated innate immunity and completely eradicated prostate cancer in a study using a mouse model.

Moderate Hypofractionation Effective, Cost-Efficient, and Tolerable in Prostate Cancer

Moderate Hypofractionation Effective, Cost-Efficient, and Tolerable in Prostate Cancer

Shorter course of higher dose radiation therapy provide effective treatment, costs less, and is easier on patients than current standard radiation therapy course.

No Association Between Vasectomy and Prostate Cancer Risk

No Association Between Vasectomy and Prostate Cancer Risk

There is no association between vasectomy and the risk of overall, high-grade, or advanced-stage prostate cancer or prostate cancer-related mortality.

Low-Fat Meal May Allow for Lower Doses of Abiraterone Acetate in Prostate Cancer Patients

Low-Fat Meal May Allow for Lower Doses of Abiraterone Acetate in Prostate Cancer Patients

A lower dose of abiraterone acetate with a low fat meal may have the same effect as taking the standard dose as recommended on an empty stomach.

Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure

Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure

Treatment expectations of individuals with metastatic prostate cancer and their health care providers often do not match.

Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer

Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer

African American men choosing active surveillance for their low-grade prostate cancer have overall poorer health than non-African American men undergoing active surveillance.

Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals

Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals

A significant difference exists in the failure to follow-up rates among patients undergoing active surveillance at university-based hospitals versus safety-net hospitals.

Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis

Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis

The Decipher genomic classifier obtained from biopsy samples was prognostic for distant metastases and prostate cancer-specific mortality.

GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible

GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible

A phase 3 study presented at the 2017 Genitourinary Cancers Symposium demonstrated the feasibility of conducting adjuvant trials.

Immunotherapy and the Future of Prostate Cancer Treatment

Immunotherapy and the Future of Prostate Cancer Treatment

Despite early failures, there may be a role for single-agent and combination immunotherapy for patients with prostate cancer.

Targeting AR Mutations Promising in Metastatic Prostate Cancer

Targeting AR Mutations Promising in Metastatic Prostate Cancer

A higher overall number of genetic alterations in cell-free circulating tumor DNA (ctDNA) were associated with worse treatment outcomes.

Adding Bicalutamide to Salvage RT Improves OS in Recurrent Prostate Cancer

Adding Bicalutamide to Salvage RT Improves OS in Recurrent Prostate Cancer

Investigators studied the effects of adding antiandrogen therapy to radiotherapy on cancer control and overall survival in men with prostate cancer recurrence after radical prostatectomy.

Clinicians May Want To Address Emotional Stress to Prevent Overtreatment of Localized Prostate Cancer

Clinicians May Want To Address Emotional Stress to Prevent Overtreatment of Localized Prostate Cancer

Some men with low-risk prostate cancer may opt for more aggressive treatments due to emotional distress.

Prostate Cancer Treatment Rates Decrease Following Changes in Treatment Recommendations

Prostate Cancer Treatment Rates Decrease Following Changes in Treatment Recommendations

The implementation of recommendations opposing regular prostate cancer screening appear to have lowered treatment rates dramatically.

Longer Dosing Interval of Zoledronic Acid May Be Acceptable for Bone Metastases

Longer Dosing Interval of Zoledronic Acid May Be Acceptable for Bone Metastases

Results from a phase 3 trial comparing a 12-week dosing interval with the standard 4-week dosing interval of zoledronic acid to reduce the incidence of skeletal-related events and pain in patients with bone metastases.

Hormone Therapy for Prostate Cancer (Fact Sheet)

Hormone Therapy for Prostate Cancer (Fact Sheet)

This fact reviews how hormone therapy may be used to treat prostate cancer, treatment options for castration-resistant prostate cancer, and side effects of hormone therapy.

Less Intense Surveillance Acceptable for Some Prostate Cancer Cases

Less Intense Surveillance Acceptable for Some Prostate Cancer Cases

Patients on active surveillance with stable disease may be candidates for less intense surveillance

Most Common Reason for Prostate Cancer Second Opinions: More Information

Most Common Reason for Prostate Cancer Second Opinions: More Information

Although many men obtain a second opinion regarding their prostate cancer care options, they seldom deviate from the original course of action.

MRI Plays a Role After Negative Prostate Biopsy

MRI Plays a Role After Negative Prostate Biopsy

Magnetic resonance imaging and MRI-targeted biopsy can facilitate detection of clinically significant prostate disease.

Cognitive Therapy Not More Effective Than Usual Care for Distress Reduction in Advanced PCa

Cognitive Therapy Not More Effective Than Usual Care for Distress Reduction in Advanced PCa

Advanced prostate cancer is associated with substantial psychosocial morbidity; therefore, this study was conducted to evaluate whether mindfulness-based cognitive therapy reduces distress in this population.

Guidelines Issued for Prostate MRI After Negative Biopsy

Guidelines Issued for Prostate MRI After Negative Biopsy

Consensus statement presents guidelines for prostate magnetic resonance imaging (MRI) in patients with negative biopsy.

Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer

Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer

[Clinical Medicine Insights: Oncology] This research examines the various mechanisms of resistance to chemotherapy in metastatic CRPC and the potential role of emerging regimens and agents in varying clinical phases of development.

Cancer Patients Benefit From Exercise Both During and After Treatment

Cancer Patients Benefit From Exercise Both During and After Treatment

Studies show better physical function and quality of life for cancer patients who do strength training or aerobic activity.

Second Opinions Rarely Change Prostate Cancer Decisions

Second Opinions Rarely Change Prostate Cancer Decisions

The impact of additional opinions on patient decision-making is limited.

Study Shows Effects of 2012 USPSTF Recommendation Against PSA Screening

Study Shows Effects of 2012 USPSTF Recommendation Against PSA Screening

Researchers report on their evaluation of the impact of the 2012 USPSTF recommendation on volumes of prostate biopsy and radical prostatectomy.

Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered

Study Suggests More Men With Prostate Cancer Would Choose Active Surveillance if it Were Offered

Researchers analyzed data from the NPCR of Sweden to determine whether more US men with prostate cancer would choose active surveillance if it were presented as a treatment option.

Snus Linked to Higher Risk of Prostate Cancer Mortality

Snus Linked to Higher Risk of Prostate Cancer Mortality

Safety of the smokeless tobacco product called into question after a study links it to increased prostate cancer mortality.

Androgen Deprivation Therapy for Prostate Cancer May Increase Dementia Risk

Androgen Deprivation Therapy for Prostate Cancer May Increase Dementia Risk

Growing evidence suggests a link between androgen deprivation therapy (ADT) and cognitive dysfunction, but whether it may contribute to the risk of dementia more broadly is unclear. In this study, researchers examined the association of ADT with subsequent development of dementia in patients with prostate cancer.

Early Post-op RT Linked to Worse Functional Outcomes in Prostate Cancer

Early Post-op RT Linked to Worse Functional Outcomes in Prostate Cancer

Radiotherapy administered postoperatively within 1 year of radical prostatectomy was associated with worse functional outcomes compared with radiotherapy administered 1 year or more after surgery.

E-HF Radiation Therapy Side Effects Comparable to CF Radiation Therapy in Prostate Cancer

E-HF Radiation Therapy Side Effects Comparable to CF Radiation Therapy in Prostate Cancer

Side effects experienced with extremely hypofractionated treatment for intermediate-risk prostate cancer were comparable to those of conventional radiation therapy at 2 years after treatment.

Postdiagnosis Physical Activity Linked to Improved Physical QoL in Prostate Cancer Survivors

Postdiagnosis Physical Activity Linked to Improved Physical QoL in Prostate Cancer Survivors

Prostate cancer survivors who maintain or begin recreational physical activity following cancer diagnosis report substantially higher quality of life than those who never exercise or stopped exercising after diagnosis.

Disease-Specific Mortality Comparable Among Treatment Options for Prostate Cancer

Disease-specific mortality rates for men with prostate cancer are comparable for 3 treatment options: active surveillance, radical prostatectomy, and external-beam radiotherapy.

Racial Disparity Exists in Receipt of High-Quality Prostate Cancer Care

Racial Disparity Exists in Receipt of High-Quality Prostate Cancer Care

Despite that most patients with newly diagnosed prostate cancer receive high-quality care, a racial disparity exists, a recent study has shown.

ADT for up to 36 Months Not Associated With Cognitive Decline

ADT for up to 36 Months Not Associated With Cognitive Decline

The long-term use of androgen deprivation therapy (ADT) for up to 36 months does not appear to be associated with cognitive decline in patients with prostate cancer.

Incidence of Early Stage Prostate Cancer Lower After USPSTF Recommendation Against PSA Testing

Incidence of Early Stage Prostate Cancer Lower After USPSTF Recommendation Against PSA Testing

Following the USPSTF recommendation against routine PSA testing in all men, incidence rates of early stage prostate cancer in men 50 years and older declined substantially, according to a recent study.

Distress Increases Likelihood of Choosing Surgery for Localized Prostate Cancer

Distress Increases Likelihood of Choosing Surgery for Localized Prostate Cancer

Emotional distress is associated with an increased likelihood of opting for surgery among men with localized prostate cancer.

Race Does Not Predict Prostate Cancer Metastasis Development

Race Does Not Predict Prostate Cancer Metastasis Development

Race is not associated with the development of metastases in patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to a recently published study.

Predictors Identified for Switching to Active Treatment in Prostate Cancer

Predictors Identified for Switching to Active Treatment in Prostate Cancer

Ethnicity influences patient decision to pursue active treatment and serial biopsies in active surveillance

ADT May Reduce Survival in African American Men With Favorable-risk Prostate Cancer

ADT May Reduce Survival in African American Men With Favorable-risk Prostate Cancer

Use of androgen suppression therapy may negatively impact survival in African American patients with favorable-risk prostate cancer.

No Association Between Erectile Dysfunction Drugs and Prostate Cancer

Despite previous research demonstrating that the use of PDE-5 inhibitors such as sildenafil, tadalafil, and vardenafil may reduce the risk for developing prostate cancer, a new study suggests that these agents do not prevent prostate cancer.

Salvage Radiotherapy at Lower PSA Levels May be Beneficial

Salvage Radiotherapy at Lower PSA Levels May be Beneficial

As salvage radiotherapy (SRT) outcomes may be affected by factors associated with prostatectomy findings, they may be positively affected when used at lower prostate-specific antigen (PSA) levels.

Quality of Life Not Affected by Active Surveillance of Prostate Cancer

Quality of Life Not Affected by Active Surveillance of Prostate Cancer

Choosing no treatment and regular check-ups didn't seem to stress men with low-risk disease

Decision Support and Shared Decision Making Help Patients Choose Plan for Low-Risk Prostate Cancer

Decision Support and Shared Decision Making Help Patients Choose Plan for Low-Risk Prostate Cancer

Using an online decision-support tool led to most men with low-risk prostate cancer choosing active surveillance with less conflict about their decision.

Researchers Estimate Familial Prostate Cancer Risk

Researchers Estimate Familial Prostate Cancer Risk

Researchers in Sweden have, for the first time, estimated the risk of developing various types of prostate cancer for men with brothers and/or fathers with the disease.

Fluid-Based Biomarkers Found Highly Predictive of Diagnosis and Prognosis in Prostate Cancer

Fluid-Based Biomarkers Found Highly Predictive of Diagnosis and Prognosis in Prostate Cancer

Analysis of proteins identified in urine has led to the discovery of proteomic signatures for prostate cancer that have the potential to serve as highly accurate noninvasive biomarkers that can identify aggressive disease before surgery.

Functional Status Linked to Treatment Choice for Prostate Cancer

Functional Status Linked to Treatment Choice for Prostate Cancer

Functional status, a person's ability to perform normal activities of daily living, is associated with treatment choice for patients with prostate cancer.

Consumption of Tree Nuts Associated With Reduced Mortality for Patients With Prostate Cancer

Consumption of Tree Nuts Associated With Reduced Mortality for Patients With Prostate Cancer

Consumption of tree nuts is associated with lower mortality rates among men with prostate cancer. It did not, however, correlate with a reduced risk of developing prostate cancer.

PET/CT Hybrid Imaging Technique Provides Accurate Guide for Prostate Cancer Biopsy

PET/CT Hybrid Imaging Technique Provides Accurate Guide for Prostate Cancer Biopsy

Prostate-specific molecular imaging at initial biopsy and preoperative planning can accurately determine and delineate the extent of prostate cancer. The imaging technique was a type of PET/CT called 68Ga-PSMA PET/CT.

Focal Laser Ablation Feasible and Safe for Treatment of Prostate Cancer

Focal Laser Ablation Feasible and Safe for Treatment of Prostate Cancer

Laser heat may soon be an option to treat prostate cancer. Focal laser ablation has been found both feasible and safe in men with intermediate risk prostate cancer.

Baseline PSA Levels in Midlife Could Predict Risk of Lethal Prostate Cancer

Baseline PSA Levels in Midlife Could Predict Risk of Lethal Prostate Cancer

Screening PSA levels at midlife could identify men who are at greater risk of developing prostate cancer later in life and who should be monitored more closely.

Alterations in Metabolic Pathways in Prostate Cancer Hint at Potential New Treatments

Alterations in Metabolic Pathways in Prostate Cancer Hint at Potential New Treatments

Castration-resistant prostate cancer (CRPC) has specific metabolic characteristics that could make it susceptible to new options for treatment.

Midlife PSA Levels Can Predict Future Lethal Prostate Cancer

Midlife PSA Levels Can Predict Future Lethal Prostate Cancer

PSA levels in midlife strongly predict future lethal prostate cancer risk in U.S. cohort.

Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication

Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication

Physical exercise may have a direct effect on cancer that is as effective as drugs for treating patients with prostate cancer, even for those with advanced stages of the disease.

Robotic Surgery Reduces Blood Loss and Length of Stay in Obese Men With Prostate Cancer

Robotic Surgery Reduces Blood Loss and Length of Stay in Obese Men With Prostate Cancer

Length of stay (LOS) and blood loss were reduced with RARP compared with open radical prostatectomy in obese men with prostate cancer who underwent surgery for their disease.

Vessel-Sparing Radiation Successfully Treats Prostate Cancer, Maintains Quality of Life

Radiation therapy delivered to the critical vessels surrounding the prostate can result in erectile dysfunction and bladder and renal irritation. Vessel-sparing radiation and an improved understanding of the anatomy of the prostate can reduce these effects.

New Research Questions Recommendations Regarding PSA Tests for Prostate Cancer Screening

New Research Questions Recommendations Regarding PSA Tests for Prostate Cancer Screening

New research results favor testing for prostate specific antigen (PSA) levels for detection of prostate cancer. PSA tests can reduce the number of fatal cases of prostate cancer by detecting disease early.

Genetic Biomarker Predictive of Peripheral Neuropathy in Patients Receiving Docetaxel for Prostate Cancer

Docetaxel-induced neuropathy may be predicted by single nucleotide polymorphisms in VAC14.

Radiotherapy Plus Hormone Therapy Improves Long-term Survival for Patients With Prostate Cancer

Radiotherapy in combination with anti-androgen hormone therapy halves the risk of death from prostate cancer 15 years after diagnosis compared with hormone therapy alone.

Hsp90 Inhibition Overcomes Hormone Resistance in Some Aggressive Prostate Cancers

The second-generation hsp90 inhibitor onalespib may be beneficial for men with prostate cancer that no longer responds to androgen deprivation therapy

Diet Can Affect Aggressiveness of Prostate Cancer

Diet Can Affect Aggressiveness of Prostate Cancer

Research also suggests that statins may help counteract harmful effect of fatty foods

Physical Activity May Improve Prostate Cancer Prognosis

Physical Activity May Improve Prostate Cancer Prognosis

A moderate to high level of physical activity before and after diagnosis may improve prognosis in patients with non-metastatic prostate cancer.

Shortened Radiation Therapy Schedule No Worse Than Conventional Radiotherapy in Low-Risk Prostate Cancer

Shortened Radiation Therapy Schedule No Worse Than Conventional Radiotherapy in Low-Risk Prostate Cancer

Treatment with a hypofractionated radiotherapy (HRT) schedule achieved similar efficacy as treatment with the longer, conventional RT (CRT) schedule in men with low-risk prostate cancer.

Urine Test Accurately Identifies Tumor Grade in Prostate Cancer

Urine Test Accurately Identifies Tumor Grade in Prostate Cancer

A new urine assay that can detect genetic changes correlated with prostate cancer correctly identified cancer grade in 92% of men with elevated PSA levels and high-grade cancers.

AACR: Regular Pre-Diagnosis Exercise Ups Prostate Cancer Survival

AACR: Regular Pre-Diagnosis Exercise Ups Prostate Cancer Survival

Researchers found that men with prostate cancer who had exercised regularly had the best outcomes.

Higher Radiation Doses May Not Improve Survival in Localized Prostate Cancer

New technology has enabled doctors to administer higher doses of radiation to prostate cancer tumors with fewer side effects; however, escalating the dose of radiation may not help patients with localized prostate cancer in the long term.

The Relationship Between Location of Metastases and Overall Survival in Men with mCRPC

The Relationship Between Location of Metastases and Overall Survival in Men with mCRPC

Site of metastasis is key to the length of time a patient can survive metastatic castration-resistant prostate cancer (mCRPC).

Noncancer-related Hospitalizations Increase After Prostate Cancer Diagnoses in Elderly Men

Noncancer-related Hospitalizations Increase After Prostate Cancer Diagnoses in Elderly Men

Men age 67 years or older with prostate cancer were 37% more likely to be hospitalized for noncancer reasons after their cancer diagnosis than before their diagnosis.

GI/GU Toxicity, Radiation Exposure Lower With IMRT vs 3DCRT for Prostate Cancer

GI/GU Toxicity, Radiation Exposure Lower With IMRT vs 3DCRT for Prostate Cancer

Radiation doses to the bladder and rectum were reduced with intensity-modulated radiotherapy (IMRT) for prostate cancer.

Higher Treatment Volumes at Radiation Facilities Lead to Improved Overall Survival in Prostate Cancer

Higher Treatment Volumes at Radiation Facilities Lead to Improved Overall Survival in Prostate Cancer

Among men with aggressive prostate cancer, overall survival (OS) rates improve when they receive radiation treatment at facilities that frequently perform the treatment.

Bicalutamide Plus Everolimus May Be Effective for CRPC

Bicalutamide Plus Everolimus May Be Effective for CRPC

The combination of bicalutamide and everolimus may be effective in men with bicalutamide-naïve castration-resistant prostate cancer (CRPC).

Surgery Improves Survival After Radiotherapy Failure in Men With Prostate Cancer

A complex surgical procedure to remove the prostate achieves excellent long-term survival for men with prostate cancer after radiation therapy has failed.

Risk for Some Secondary Cancers After Radiotherapy For Prostate Cancer is Increased

Although reported absolute rates of second malignancies after radiotherapy for prostate cancer are very low, it is associated with higher rates of bladder, colon, and rectal cancers in patients who undergo radiotherapy for prostate cancer.

Serum Vitamin D Levels Predict Adverse Pathology at Prostatectomy

Both insufficiency and deficiency of serum vitamin D correlated with an increased risk of unfavorable pathology in men undergoing radical prostatectomy for prostate cancer.

Opting for Active Surveillance Increasing Among Men With Low-grade Prostate Cancer

Patients with slow-growing prostate cancer are increasingly opting for active surveillance and only changing treatment plan if the disease changes to a higher risk form to avoid unnecessary and potentially toxic treatments.

Short Androgen Suppression With RT Improves DFS in Localized Prostate Cancer

Short Androgen Suppression With RT Improves DFS in Localized Prostate Cancer

Adding 6 months of adjuvant androgen suppression to radiotherapy improves biochemical and clinical disease-free survival (DFS).

Use of Proton Therapy for Prostate Cancer Has Doubled

Use of Proton Therapy for Prostate Cancer Has Doubled

The use of proton therapy to treat patients with prostate cancer increased more than 2-fold from 2004 to 2012.

Overall Survival in mCRPC Worse for Men With Lung, Liver Metastases

Overall Survival in mCRPC Worse for Men With Lung, Liver Metastases

Overall survival (OS) is worse for men with castration-resistant prostate cancer (CRPC) metastases to the lung and liver.

Few Older Men Receiving Recommended Intensity of Active Surveillance

Few Older Men Receiving Recommended Intensity of Active Surveillance

Very few older man receive the intensity of active surveillance testing recommended by major prospective active surveillance (AS) programs.

Diagnostic Tool Can Smell Bladder Cancer or Prostate Cancer in a Urine Sample

Diagnostic Tool Can Smell Bladder Cancer or Prostate Cancer in a Urine Sample

Recent developments in a gas chromatography tool might allow doctors to determine whether urologic cancers are present via a urine sample.

Colorectal Cancer Risk Higher for Patients With a Prostate Cancer Diagnosis

Colorectal Cancer Risk Higher for Patients With a Prostate Cancer Diagnosis

The risk for developing colorectal cancer is increased after a diagnosis of prostate cancer.

Data Analyses Reveal Radium-223 Improves Quality of Life Measures for CRPC

Data Analyses Reveal Radium-223 Improves Quality of Life Measures for CRPC

Radium-223 dichloride (radium-223) improves overall survival in patients with castration-resistant prostate cancer (CRPC).

Heart Disease Is Most Common Cause of Death for Prostate Cancer Survivors

Survivors of prostate cancer should be made aware of an increased risk for heart disease. It is the most common noncancer cause of death for men with prostate cancer.

Novel Therapeutic Demonstrates Effectiveness Against Castration-resistant Prostate Cancer

The growth of castration-resistant prostate cancer cells was reduced by a first-in-class sphingosine kinase 2 inhibitor, but the cells were not killed.

Skeletal-related Events Linked With Worse Survival, Increased Costs

Men with prostate cancer and bone metastases that have experienced at least one skeletal-related event (SRE) show worse survival, according to a recent study.

PET Imaging Promising for Metastatic Prostate Cancer

PET Imaging Promising for Metastatic Prostate Cancer

Positron emission tomography (PET) imaging may offer a superior method of imaging for metastatic prostate cancer.

Prostate-Specific Antigen (PSA) Test (Fact Sheet)

Prostate-Specific Antigen (PSA) Test (Fact Sheet)

This fact sheet reviews the PSA test for prostate cancer, in particular screening recommendations, test limitations, and possible improvements the future may hold in store for the test.

Rates of Nonrecommended Screenings for Prostate and Breast Cancers Is High Among Older Patients

Among persons 65 years or older with limited life expectancies of less than 10 years, an estimated 15.7% may have undergone nonrecommended screenings for prostate and breast cancers.

CRPC: Enzalutamide Better Than Bicalutamide for Improving PFS

CRPC: Enzalutamide Better Than Bicalutamide for Improving PFS

Enzalutamide significantly reduced the risk of prostate cancer progression or death in prostate cancer.

Some Improvements in Survival, Skeletal Events Seen in Clinical Trial of Docetaxel Combo

Some Improvements in Survival, Skeletal Events Seen in Clinical Trial of Docetaxel Combo

Phase 3 results of the TRAPEZE trial of patients with bony metastatic castrate-refractory prostate cancer (CRPC).

Lethal Prostate Cancer Risk Lower With Regular Aspirin Use

Lethal Prostate Cancer Risk Lower With Regular Aspirin Use

The risk of lethal prostate cancer, but not of overall, high-grade, or advanced cancers, was reduced with regular aspirin use.

Novel Diagnostic Test Uses CTCs in Blood to Guide Treatment Decisions for Patients With Prostate Cancer

An experimental liquid biopsy using a blood sample may determine which patients with prostate cancer will benefit from hormone therapies.

Prostate Cancer Screening and Treatment Information Inadequate for Most Men

Prostate Cancer Screening and Treatment Information Inadequate for Most Men

Important discussions about prostate cancer screening and treatment are not occurring between men and their health care team.

In mCRPC, Docetaxel Active After Antiandrogen Therapy

A total of 40% of patients with mCRPC treated with docetaxel after abiraterone achieved at least a 50% reduction in PSA, according to a study presented at the 2016 Genitourinary Cancers Symposium.

Active Surveillance Criteria for Early Prostate Cancer May Not Be Accurate in African American Men

Active Surveillance Criteria for Early Prostate Cancer May Not Be Accurate in African American Men

African American men with Gleason score 3+3=6 prostate cancer produce less PSA and have significantly lower PSA density than white men, according to a new study. These findings could have important implications for treatment decision-making.

Risks of Adverse Effects Lower With Surgical Castration Vs. Chemical Castration for Metastatic Prostate Cancer

Surgical castration via orchiectomy for metastatic prostate cancer is associated with lower risks for adverse effects compared with medical castration via GnRHa therapy.

Familial Risk and Heritability of Cancer Is Higher Among Twins

Twins carry a significant excess familial risk for cancer overall and for specific types of cancer, including prostate, melanoma, breast, ovary, and uterus, according to a long-term follow-up study of twins in Nordic countries.

GnRH Agonists Associated With Higher Adverse Effect Risk vs Orchiectomy

Gonadotropin-releasing hormone agonist (GnRHa) therapy is associated with increased risks of numerous clinically relevant adverse events compared with orchiectomy.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs